MPRIP Antibody

What is MPRIP and why is it important in cellular research?

MPRIP (Myosin Phosphatase Rho Interacting Protein), also known as p116Rip, MRIP, or RHOIP3, is a critical regulator of the actin cytoskeleton. It functions by targeting myosin phosphatase to the actin cytoskeleton and is required for the regulation of the actin cytoskeleton by RhoA and ROCK1. The protein's significance lies in its dual role: in the cytoplasm, it modulates stress fiber formation in various cell types, while in the nucleus, it participates in transcriptional regulation through interactions with nuclear actin and RNA Polymerase II. Depletion of MPRIP leads to an increased number of stress fibers in smooth muscle cells through stabilization of actin fibers by phosphorylated myosin, whereas overexpression results in disassembly of stress fibers in neuronal cells . Recent research has expanded our understanding of MPRIP to include its role as a PIP2-effector that determines the association of RNAPII with PIP2, highlighting its importance in nuclear processes .

What epitopes do commercially available MPRIP antibodies typically recognize?

Commercial MPRIP antibodies target various regions of the protein, providing researchers with options based on experimental requirements. For instance, some antibodies like Abcam's ab251741 recognize the C-terminal region, specifically targeting recombinant fragment protein within Human MPRIP aa 850 to C-terminus . Others, such as Abbexa's antibody, are raised against synthesized peptides derived from internal regions of human MPRIP, with the immunogenic sequence CQRQHQRELEKLREE . This diversity allows researchers to select antibodies that target distinct domains of MPRIP, which is particularly important when studying different isoforms or when certain epitopes might be masked in specific cellular contexts or experimental conditions.

How do I determine which MPRIP antibody is most suitable for my specific experimental application?

Selecting the appropriate MPRIP antibody requires consideration of several factors:

• Application compatibility: Verify the antibody has been validated for your intended application (IHC-P, WB, ICC/IF, or ELISA). For example, ab251741 has been validated for IHC-P, WB, and ICC/IF applications , while some antibodies like the one from Abbexa are validated for ELISA and IHC .

• Species reactivity: Confirm the antibody recognizes MPRIP in your species of interest. Many antibodies react with human, mouse, and rat MPRIP .

• Targeted region: Consider which domain of MPRIP is relevant to your research. If studying nuclear functions, an antibody recognizing the C-terminal region might be preferable, as this contains PH domains important for nuclear interactions .

• Validation evidence: Review the validation data provided by manufacturers, including images of western blots, immunocytochemistry, or immunohistochemistry results.

• Literature precedent: Search for publications that have successfully used specific antibodies for applications similar to yours.

For nuclear localization studies, antibodies that have been specifically validated in nuclear fractionation experiments would be most appropriate, as demonstrated in the research showing MPRIP's nuclear presence .

What protocol modifications are recommended for optimal immunocytochemical detection of nuclear MPRIP?

For successful detection of nuclear MPRIP by immunocytochemistry, consider these methodological adjustments:

• Fixation optimization: Use paraformaldehyde (PFA) fixation followed by Triton X-100 permeabilization as demonstrated in successful studies. Specifically, 4% PFA fixation for 15 minutes at room temperature, followed by 0.1% Triton X-100 permeabilization for 10 minutes has proven effective .

• Antibody concentration: Higher concentrations than typically used for cytoplasmic proteins may be necessary; for example, 4 μg/ml of antibody has been successfully used for nuclear MPRIP detection in ICC/IF applications .

• Extended incubation times: Consider overnight primary antibody incubation at 4°C to improve nuclear penetration.

• Nuclear counterstaining: Include DAPI or other nuclear stains to clearly delineate nuclear boundaries when visualizing the granular pattern of nuclear MPRIP.

• Confocal microscopy settings: Use thin optical sections (0.5-1 μm) to properly distinguish nuclear from cytoplasmic staining, as MPRIP displays a granular pattern dispersed in the nucleoplasm .

• Controls: Include cells treated with MPRIP siRNA or esiRNA as negative controls to confirm specificity of nuclear staining pattern .

How can I validate the specificity of MPRIP antibody staining in my experimental system?

Validating antibody specificity is crucial for reliable results. Implement these approaches:

• Genetic knockdown: Utilize MISSION esiRNA targeting MPRIP (such as EHU141181) for post-transcriptional silencing, comparing antibody staining in knocked-down versus control cells. This approach reduces off-target effects due to the pool of siRNAs at approximately 50 pM concentration each .

• Overexpression controls: Express GFP-tagged MPRIP (full-length or domains) and perform co-localization studies with antibody staining .

• Multiple antibodies: Compare staining patterns using antibodies recognizing different epitopes of MPRIP, such as HPA022901 (Sigma) and sc-515720 (Santa Cruz) .

• Western blot validation: Confirm the antibody detects a band of the expected molecular weight (~120 kDa) in your cell type/tissue .

• Subcellular fractionation: Perform nuclear and cytoplasmic fractionation followed by western blot to verify the presence of MPRIP in nuclear fractions, using Lamin B and GAPDH as fractionation quality controls .

• Peptide competition: Pre-incubate the antibody with the immunogenic peptide before application to demonstrate binding specificity.

What dilution ranges and incubation conditions work best for MPRIP antibodies in various applications?

These recommendations serve as starting points; optimal conditions should be determined empirically for each experimental system. For nuclear detection, longer incubation times or slightly higher antibody concentrations may be necessary compared to protocols optimized for cytoplasmic protein detection.

How can MPRIP antibodies be utilized to study its phase separation properties and interactions with nuclear actin?

MPRIP has been shown to form phase-separated condensates in the nucleus, providing an exciting research avenue. To study these properties:

• Live-cell imaging: Combine GFP-MPRIP expression with antibody staining of endogenous proteins to correlate condensate formation with specific cellular conditions or treatments .

• Co-immunoprecipitation: Use MPRIP antibodies for immunoprecipitation followed by mass spectrometry or western blot to identify interaction partners within the condensates. This approach has successfully identified MYO1C and active RNAPII as nuclear interactors of MPRIP .

• 1,6-hexanediol sensitivity: Treat cells with 1,6-hexanediol before fixation and MPRIP antibody staining to determine if the observed nuclear structures are formed through phase separation .

• FRAP analysis: Perform fluorescence recovery after photobleaching on GFP-MPRIP condensates, then validate with antibody staining to confirm that endogenous structures behave similarly.

• Co-localization with nuclear actin: Use MPRIP antibodies in combination with nuclear actin probes to visualize interactions between MPRIP and nuclear actin fibers. These studies have revealed that MPRIP condensates can bind nuclear actin fibers, displaying liquid-like properties even when bound to fibrous structures .

• PIP2 co-detection: Employ anti-PI(4,5)P2 antibodies (such as Z-A045, clone 2C11) alongside MPRIP antibodies to examine co-localization in nuclear speckles and investigate MPRIP's role as a PIP2-effector in transcriptional regulation .

What approaches can be used to study MPRIP's role in transcriptional regulation using antibodies?

MPRIP has emerged as a novel transcription regulator that determines the association of RNAPII with PIP2. To investigate this function:

• Chromatin immunoprecipitation (ChIP): Use MPRIP antibodies for ChIP experiments to identify genomic regions where MPRIP associates with chromatin.

• Co-IP with transcriptional machinery: Immunoprecipitate MPRIP and probe for components of the transcriptional machinery, including RNAPII with phosphorylated CTD at Serine 5 (ab5131) .

• Nuclear speckle co-localization: Perform double immunostaining with MPRIP antibodies and markers of nuclear speckles to confirm localization to these transcriptionally active domains .

• Transcriptional activity assays: Compare transcriptional output in cells with normal versus depleted MPRIP levels (using siRNA approaches), and use MPRIP antibodies to confirm knockdown efficiency.

• Proximity ligation assay (PLA): Employ PLA to detect and quantify interactions between MPRIP and components of the transcriptional machinery in situ, providing spatial resolution of these interactions within the nucleus.

• Combined with functional genomics: Integrate MPRIP antibody-based assays with RNA-seq following MPRIP depletion to correlate MPRIP binding with transcriptional outcomes.

How do the different domains of MPRIP contribute to its cellular functions, and how can domain-specific antibodies help elucidate these roles?

MPRIP contains multiple functional domains, including PH domains for PIP2 interaction and regions that mediate actin binding. Domain-specific approaches can reveal their distinct contributions:

• Domain mapping studies: Use antibodies recognizing different MPRIP domains in conjunction with expression of domain-specific constructs (N-terminal 1-450aa or C-terminal 450-1000aa fragments) .

• Structure-function analysis: Compare localization patterns of full-length versus truncated MPRIP using domain-specific antibodies to determine which regions are required for nuclear localization, stress fiber association, or condensate formation.

• NLS validation: The predicted nuclear localization signal (NLS) at residues 155-164 can be studied using antibodies that specifically recognize this region or flanking sequences, combined with mutagenesis of this conserved element .

• PH domain interactions: Investigate how MPRIP's two PH domains contribute to PIP2 binding and nuclear functions using antibodies that specifically recognize these domains, coupled with biochemical assays of lipid binding.

• F-actin binding region: Determine how the F-actin binding region contributes to both cytoplasmic and nuclear functions by using antibodies specific to this region in cells expressing wild-type versus mutant MPRIP.

• Phosphorylation status: Develop or utilize phospho-specific antibodies to examine how post-translational modifications regulate MPRIP's distribution between cytoplasmic and nuclear compartments.

What are common pitfalls when working with MPRIP antibodies, and how can researchers overcome them?

Researchers often encounter several challenges when working with MPRIP antibodies:

• High background in immunostaining: This may result from inadequate blocking or excessive antibody concentration. Solutions include:

  • Extend blocking time to 2 hours using 5% BSA or 10% serum from the species of the secondary antibody

  • Test a range of primary antibody dilutions (1:50 to 1:500)

  • Include 0.1% Tween-20 in wash buffers to reduce non-specific binding

• Weak nuclear signal: Nuclear MPRIP detection can be challenging due to its granular pattern and lower abundance compared to cytoplasmic MPRIP . Improvements include:

  • Optimize fixation and permeabilization protocols specifically for nuclear proteins

  • Use antigen retrieval methods for tissue sections

  • Employ signal amplification systems such as tyramide signal amplification

• Inconsistent western blot results: MPRIP's large size (~120 kDa) can make protein transfer inefficient. Optimize by:

  • Using longer transfer times or semi-dry transfer systems

  • Reducing SDS-PAGE gel percentage to 6-8% for better resolution of high molecular weight proteins

  • Adding SDS (0.1%) to transfer buffer to improve transfer efficiency

• Antibody cross-reactivity: Some antibodies may recognize related proteins. Validate specificity by:

  • Performing knockdown controls

  • Testing multiple antibodies targeting different epitopes

  • Including biological negative controls (tissues or cells known not to express MPRIP)

• Variable results between experiments: Standardize protocols by:

  • Maintaining consistent cell culture conditions

  • Using the same lot of antibody when possible

  • Implementing quantitative analysis methods to normalize staining intensity

How can researchers distinguish between cytoplasmic and nuclear MPRIP pools when both are present in the same cell?

Differentiating between cytoplasmic and nuclear MPRIP requires careful methodological approaches:

• Confocal microscopy with Z-stacking: Acquire thin optical sections (0.5 μm) through cells to clearly resolve nuclear versus cytoplasmic signals, then create maximum intensity projections or 3D reconstructions.

• Nuclear counterstaining: Use DAPI or other nuclear markers to precisely define nuclear boundaries.

• Subcellular fractionation: Separate nuclear and cytoplasmic fractions biochemically, then analyze by western blot, using Lamin B and GAPDH as fractionation quality controls .

• Structured illumination microscopy (SIM): Apply super-resolution techniques to better resolve the granular pattern of nuclear MPRIP from cytoplasmic signals.

• Photo-convertible tags: For live-cell studies, use photo-convertible fluorescent protein-tagged MPRIP to track movement between compartments, validating observations with antibody staining of fixed cells.

• Domain-specific antibodies: Utilize antibodies targeting domains that may be differentially exposed in nuclear versus cytoplasmic environments.

• Computational image analysis: Implement algorithms that quantify signal intensity in defined nuclear versus cytoplasmic regions of interest across multiple cells.

How do different fixation methods affect the detection of MPRIP in various cellular compartments?

Fixation methodology significantly impacts MPRIP detection, particularly for its nuclear pool:

For optimal nuclear MPRIP detection, research has shown that PFA fixation followed by Triton X-100 permeabilization works well when using appropriate antibody concentrations, such as 4 μg/ml in ICC/IF applications .

How might MPRIP antibodies contribute to understanding the protein's role in disease processes?

MPRIP's dual role in cytoskeletal regulation and transcriptional control suggests potential involvement in various pathological conditions. Antibody-based approaches can help elucidate these connections:

• Cancer research: Investigate MPRIP expression and localization in tumor versus normal tissues using immunohistochemistry, focusing on cancers where cytoskeletal dysregulation is prominent.

• Cardiovascular disorders: Examine MPRIP's role in smooth muscle cell function using antibodies to assess expression patterns in normal versus diseased vascular tissue, given its known function in stress fiber regulation .

• Neurodegenerative diseases: Explore potential roles in neuronal function through antibody-based detection in brain tissues, particularly since MPRIP overexpression affects stress fiber disassembly in neuronal cells .

• Transcription-related disorders: Investigate whether MPRIP's nuclear functions and interactions with transcriptional machinery contribute to disorders characterized by transcriptional dysregulation.

• Biomarker development: Assess whether MPRIP antibodies could serve as diagnostic or prognostic tools based on altered expression or localization patterns in disease states.

• Therapeutic target validation: Use antibodies to confirm target engagement in preclinical studies if MPRIP pathways prove relevant for therapeutic intervention.

What emerging techniques might enhance the utility of MPRIP antibodies in research applications?

Several cutting-edge approaches can extend the applications of MPRIP antibodies:

• Proximity proteomics: Combine MPRIP antibodies with BioID or APEX2 approaches to comprehensively map protein interactions in living cells.

• Spatial transcriptomics: Integrate MPRIP immunostaining with spatial transcriptomics to correlate its nuclear localization with gene expression patterns at the single-cell level.

• Live-cell immunolabeling: Adapt antibody fragments for live-cell applications to track MPRIP dynamics in real-time, particularly during phase separation and fiber formation events .

• Cryo-electron tomography: Combine with immuno-gold labeling to visualize MPRIP's association with nuclear structures at nanoscale resolution.

• Antibody-based optogenetic tools: Develop systems to manipulate MPRIP function in specific cellular compartments using antibody-based targeting of optogenetic modules.

• Single-molecule imaging: Apply techniques like STORM or PALM with MPRIP antibodies to study the molecular organization of MPRIP within phase-separated condensates and its interaction with nuclear actin at super-resolution.

• CRISPR-mediated tagging: Use CRISPR/Cas9 to insert tags into endogenous MPRIP for tracking, then validate observations with antibody-based approaches to ensure tagged protein behaves like the native form.